|
ACS Nano
|
2 |
0.07 |
|
|
|
Acta Biomaterialia
|
4 |
3.83 |
|
|
|
Advanced Materials
|
1 |
0.15 |
|
|
|
American Journal of Clinical Nutrition
|
2 |
0.17 |
|
|
|
American Journal of Human Genetics
|
4 |
0.36 |
|
|
|
American Journal of Obstetrics and Gynecology
|
3 |
1.48 |
|
|
|
American Journal of Pathology
|
2 |
1.55 |
|
|
|
American Journal of Respiratory and Critical Care Medicine
|
6 |
1.27 |
|
|
|
Analytical Chemistry
|
1 |
0.60 |
|
|
|
Anesthesiology
|
9 |
5.02 |
|
|
|
Annals of Emergency Medicine
|
4 |
2.17 |
|
|
|
Annals of Family Medicine
|
1 |
1.00 |
|
|
|
Annals of Internal Medicine
|
7 |
4.23 |
|
|
|
Annals of Neurology
|
3 |
0.98 |
|
|
|
Annals of Surgery
|
3 |
2.04 |
|
|
|
Annals of the Rheumatic Diseases
|
11 |
5.04 |
|
|
|
Archives of Physical Medicine and Rehabilitation
|
3 |
3.00 |
|
|
|
Arthritis & Rheumatology
|
20 |
7.14 |
|
Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis within a Longitudinal Cohort
|
0.78 |
|
High‐resolution deep learning DIXON MRI of the sacroiliac joints is non‐inferior to standard MRI in patients with suspected axial Spondyloarthritis
|
0.04 |
|
Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients: An ARChiVe Study
|
0.34 |
|
18F‐Fluorodeoxyglucose Positron Emission Tomography Imaging Assessment within a Randomized Controlled Trial in Giant Cell Arteritis
|
0.08 |
|
Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration
|
0.09 |
|
Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study
|
0.08 |
|
Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data
|
1.00 |
|
Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study
|
0.96 |
|
Association of Clonal Hematopoiesis With Incident, Late‐Onset, Seropositive Rheumatoid Arthritis
|
0.11 |
|
Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases
|
1.00 |
|
Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease
|
0.11 |
|
The impact of non‐steroidal anti‐inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: 10‐year results from an inception cohort
|
0.06 |
|
Toward a treat‐to‐target strategy in juvenile dermatomyositis: what are the suitable targets and optimal timing of their achievement?
|
0.32 |
|
Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN‐DU study
|
0.31 |
|
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With scpJAK/scp Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
|
0.03 |
|
Clinical Impact of Multiparametric Contrast‐Enhanced Dual‐Energy Computed Tomography in Arthritis Imaging: A Prospective Single‐Center Study
|
0.05 |
|
Differences in IgG Sialylation Distinguish Asymptomatic from Symptomatic Anti‐Nuclear Antibody Positive Individuals
|
1.00 |
|
Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies
|
0.40 |
|
Three‐Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular scpJIA/scp Consensus Treatment Plans Study
|
0.22 |
|
A randomized, double‐blind, placebo‐controlled trial of abatacept for the treatment of relapsing, non‐severe, granulomatosis with polyangiitis
|
0.17 |
|
|
Brain
|
2 |
0.43 |
|
|
|
British Journal of Surgery
|
3 |
1.85 |
|
|
|
Cell
|
4 |
0.94 |
|
|
|
Cell Host & Microbe
|
2 |
0.26 |
|
|
|
Cell Metabolism
|
1 |
0.05 |
|
|
|
Chemical Science
|
1 |
0.13 |
|
|
|
Chest
|
5 |
3.15 |
|
|
|
Circulation
|
3 |
1.01 |
|
|
|
Clinical Infectious Diseases
|
5 |
2.93 |
|
|
|
Critical Care Medicine
|
15 |
7.55 |
|
|
|
Current Biology
|
4 |
3.38 |
|
|
|
Developmental Cell
|
2 |
0.90 |
|
|
|
Diabetes Care
|
9 |
3.58 |
|
|
|
Environmental Health Perspectives
|
2 |
0.15 |
|
|
|
Environmental Pollution
|
2 |
1.36 |
|
|
|
Environmental Research
|
4 |
1.97 |
|
|
|
Environmental Science and Technology
|
3 |
1.87 |
|
|
|
European Heart Journal
|
3 |
0.15 |
|
|
|
European Urology
|
2 |
0.05 |
|
|
|
Gastroenterology
|
4 |
0.39 |
|
|
|
Genome Research
|
1 |
0.20 |
|
|
|
Gut
|
8 |
1.17 |
|
|
|
Hepatology
|
6 |
1.42 |
|
|
|
Immunity
|
1 |
0.30 |
|
|
|
International Journal of Epidemiology
|
1 |
0.50 |
|
|
|
JAMA Internal Medicine
|
5 |
1.74 |
|
|
|
JAMA Pediatrics
|
4 |
1.47 |
|
|
|
JAMA Psychiatry
|
7 |
3.06 |
|
|
|
JAMA Surgery
|
3 |
2.97 |
|
|
|
JAMA: The Journal of the American Medical Association
|
8 |
1.90 |
|
|
|
Journal of Biological Chemistry
|
2 |
1.77 |
|
|
|
Journal of Bone and Joint Surgery-American Volume
|
16 |
6.23 |
|
|
|
Journal of Clinical Endocrinology & Metabolism
|
9 |
4.55 |
|
|
|
Journal of Clinical Investigation
|
2 |
0.83 |
|
|
|
Journal of Clinical Oncology
|
2 |
0.38 |
|
|
|
Journal of Hepatology
|
8 |
2.45 |
|
|
|
Journal of Infectious Diseases
|
17 |
8.06 |
|
|
|
Journal of Neuroscience
|
13 |
10.32 |
|
|
|
Journal of Physiology
|
14 |
8.27 |
|
|
|
Journal of Thoracic and Cardiovascular Surgery
|
10 |
7.39 |
|
|
|
Journal of the American Academy of Child and Adolescent Psychiatry
|
1 |
0.08 |
|
|
|
Journal of the American Academy of Dermatology
|
6 |
0.56 |
|
|
|
Journal of the American Chemical Society
|
1 |
0.70 |
|
|
|
Journal of the American College of Cardiology
|
3 |
0.16 |
|
|
|
Journal of the American Geriatrics Society
|
10 |
8.85 |
|
|
|
Journal of the American Society of Nephrology
|
8 |
1.89 |
|
|
|
Journal of the National Cancer Institute
|
4 |
0.49 |
|
|
|
Kidney International
|
7 |
2.57 |
|
|
|
Molecular Psychiatry
|
22 |
7.52 |
|
|
|
Nature
|
6 |
1.92 |
|
|
|
Nature Communications
|
53 |
16.41 |
|
|
|
Nature Genetics
|
4 |
0.40 |
|
|
|
Nature Immunology
|
2 |
0.06 |
|
|
|
Nature Medicine
|
15 |
5.48 |
|
|
|
Nature Methods
|
2 |
1.56 |
|
|
|
Nature Neuroscience
|
2 |
0.19 |
|
|
|
Nature Structural & Molecular Biology
|
1 |
0.50 |
|
|
|
Neuron
|
5 |
2.05 |
|
|
|
PLOS Biology
|
2 |
0.48 |
|
|
|
PLOS Genetics
|
2 |
1.17 |
|
|
|
PLOS Medicine
|
4 |
2.47 |
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
|
14 |
8.97 |
|
|
|
Proceedings of the Royal Society B
|
2 |
0.58 |
|
|
|
Radiology
|
4 |
1.11 |
|
|
|
Science
|
1 |
0.35 |
|
|
|
Science Advances
|
8 |
4.84 |
|
|
|
Science Translational Medicine
|
5 |
1.36 |
|
|
|
The BMJ
|
4 |
0.64 |
|
|
|
The EMBO Journal
|
1 |
0.03 |
|
|
|
The ISME Journal: Multidisciplinary Journal of Microbial Ecology
|
1 |
0.75 |
|
|
|
The Journal of Allergy and Clinical Immunology
|
5 |
0.83 |
|
|
|
The Lancet
|
8 |
0.69 |
|
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
|
0.05 |
|
Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation
|
0.02 |
|
Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study
|
0.03 |
|
Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial
|
0.08 |
|
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis
|
0.02 |
|
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
|
0.13 |
|
Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials
|
0.28 |
|
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
|
0.09 |
|
|
The Lancet Diabetes & Endocrinology
|
2 |
1.13 |
|
|
|
The Lancet Global Health
|
1 |
0.50 |
|
|
|
The Lancet Neurology
|
2 |
1.13 |
|
|
|
The Lancet Psychiatry
|
2 |
0.86 |
|
|
|
The New England Journal of Medicine
|
15 |
2.93 |
|
|
|
Water Research
|
2 |
0.42 |
|
|